Scarica l'app Stockscreener
19.56
0.61%
-0.12
Dopo l'orario di chiusura:
19.37
-0.19
-0.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.68
Aprire:
$19.73
Volume 24 ore:
1.15M
Relative Volume:
1.66
Capitalizzazione di mercato:
$1.07B
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-8.2532
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
+7.41%
1M Prestazione:
+44.14%
6M Prestazione:
+134.81%
1 anno Prestazione:
+42.25%
Intervallo 1D:
$19.13
$19.91
Intervallo di 1 settimana:
$17.95
$19.91
Portata 52W:
$5.35
$19.91
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
19.56 | 1.01B | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics Executives Sell Shares to Cover Tax Liabilities - TradingView
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - Eastern Progress
Stoke Therapeutics stock hits 52-week high at $18.61 - Investing.com India
Stoke Therapeutics stock hits 52-week high at $18.61 By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise 1.27% intraday after announcing inducement grants to new employees. - AInvest
Stoke Therapeutics shares fall 3.24% premarket after Purcell & Lefkowitz LLP announces shareholder investigation. - AInvest
Stoke Therapeutics' Strategic Stock Grants: Fueling Leadership Stability and Long-Term Value Creation in Biotech - AInvest
Stoke Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News - GuruFocus
Stoke Therapeutics Inc. Approaches Psychological Resistance LevelWeekly Volume Report & Weekly Sector Rotation Insights - classian.co.kr
BTIG Maintains Buy Rating on Stoke Therapeutics with $28 Price Target - AInvest
Purcell & Lefkowitz LLP Investigates Stoke Therapeutics on Shareholder Breach of Fiduciary Duties - AInvest
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - MarketScreener
Stoke Therapeutics price target lowered to $28 from $29 at BTIG - TipRanks
Stoke Therapeutics stock price target lowered to $28 at BTIG on Zorevunersen data - Investing.com
Watch for Trend Continuation in Stoke Therapeutics Inc. Next WeekQuarterly Trade Report & Free Expert Approved Momentum Trade Ideas - beatles.ru
Building trade automation scripts for Stoke Therapeutics Inc.Market Volume Summary & Safe Capital Growth Tips - Newser
Multi asset correlation models including Stoke Therapeutics Inc.July 2025 Selloffs & Real-Time Volume Analysis - Newser
Cantor Fitzgerald Has Positive View of STOK FY2025 Earnings - Defense World
Ranking Stoke Therapeutics Inc. among high performing stocks via toolsRisk Management & Free Expert Verified Stock Movement Alerts - Newser
Stoke Therapeutics Receives Buy Rating from Leerink Partners with $18 Price Target - AInvest
HC Wainwright Analysts Lift Earnings Estimates for STOK - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Defense World
Is Stoke Therapeutics Inc. stock ready for a breakoutMarket Sentiment Report & Low Risk Profit Maximizing Plans - Newser
What MACD and RSI say about Stoke Therapeutics Inc.July 2025 Analyst Calls & Expert Approved Momentum Ideas - Newser
Biogen Shares Surge 2.71% on $230M Volume Boosted by Pipeline Progress Ranks 444th in Market Activity - AInvest
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) By Investing.com - Investing.com Nigeria
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Shareholders Are up 30% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
How Stoke Therapeutics Inc. stock performs during market volatility2025 Growth vs Value & Consistent Return Investment Signals - thegnnews.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate - simplywall.st
Stoke Therapeutics Inc. May Be Forming Higher Low — Chartwatchers Alert2025 Key Highlights & Capital Efficiency Focused Ideas - beatles.ru
Wedbush Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock - Defense World
Stoke Therapeutics Inc. Stock Poised for Technical ComebackMarket Activity Recap & Daily Stock Momentum Reports - newsimpact.co.kr
Stocks With Rising Relative Price Strength: Stoke Therapeutics - MSN
Healthcare Stocks Under Analyst Spotlight: Lyra Therapeutics, Stoke Therapeutics, and Astria Therapeutics. - AInvest
Stoke Therapeutics Impresses With Strong Results For Dravet Syndrome Drug - Finimize
Stoke Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Given Buy Rating at Chardan Capital - Defense World
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Strong Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High on Analyst Upgrade - Defense World
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Stoke Therapeutics Skyrockets 25.57%—What’s Fueling This Biotech Surge? - AInvest
Stoke Therapeutics Reports 'Impressive' Data for Severe Epilepsy Treatment, Wedbush Says - MarketScreener
Stoke Therapeutics Launches Global Phase III Trial of Zorevunersen for Dravet Syndrome. - PharmiWeb.com
Stoke Therapeutics shares rise 3.10% premarket after dosing first patient in Phase 3 trial of Zorevunersen for Dravet Syndrome. - AInvest
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating - TipRanks
Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating - TipRanks
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Stoke Therapeutics Inc Azioni (STOK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 14 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
25,631 |
| Kaye Edward M. MD | Director |
Aug 14 '25 |
Option Exercise |
0.00 |
26,250 |
0 |
165,596 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 13 '25 |
Sale |
15.00 |
13,712 |
205,680 |
19,631 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):